Medindia

X

MiddleBrook to Webcast Management Presentation at the 10th Annual Rodman & Renshaw Healthcare Conference

Wednesday, October 15, 2008 General News J E 4
Advertisement
GERMANTOWN, Md., Oct. 14 MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK), a pharmaceutical company focused on developing and commercializing novel anti-infective products, today announced that MiddleBrook President and CEO John Thievon will be presenting at the Rodman & Renshaw 10th Annual Healthcare Conference at the New York Palace Hotel in New York City on Nov. 11, 2008, at 12:00 p.m. (ET).



A live audio webcast of the presentation can be accessed by going to the Events section of MiddleBrook's Investor Relations web site at http://ir.middlebrookpharma.com. A replay of the webcast will be available later that day.



About Middlebrook Pharmaceuticals:

MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) is a pharmaceutical company focused on the development and commercialization of anti-infective drug products that fulfill substantial unmet medical needs in the treatment of infectious disease. The Company is developing anti-infective drugs based on its novel biological finding that bacteria exposed to antibiotics in pulses are killed more efficiently than those under standard treatment regimens. Based on this finding, MiddleBrook has developed a proprietary, once-a-day pulsatile delivery technology called PULSYS(R). The Company currently markets the Keflex(R) brand of cephalexin and has received regulatory approval for MOXATAG(TM) - the first and only once-daily amoxicillin product approved for marketing in the U.S. For more information on MiddleBrook, please visit www.middlebrookpharma.com.





SOURCE MiddleBrook Pharmaceuticals, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Avidas Pharmaceuticals Signs Agreement to Acquire ...
S
Paratek to Present Clinical Data in Late Breaker P...